# Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

> **NCT00415519** · PHASE3 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 25 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** MCI-186
- **DRUG:** Placebo of MCI-186

## Key facts

- **NCT ID:** NCT00415519
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415519, "Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00415519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*